Quintiles has announced a strategic agreement with Pharmaxis to provide a broad range of commercial solutions to support the European launch of Bronchitol^®, an innovative treatment for cystic fibrosis.

As a result of the agreement, Quintiles will execute a comprehensive commercialization effort for Bronchitol across Western Europe. Beginning with Germany in early 2011, Quintiles will later support the commercialization of Bronchitol in France, Spain, Italy, Austria, Switzerland, the Netherlands, Belgium, Luxemburg and Portugal. Quintiles’ services include development of the overall market access strategy, pricing and reimbursement, local market access, product management, and recruitment and management of field-based commercial teams.

Designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions, Bronchitol has been awarded orphan drug designation for cystic fibrosis in the European Union and United States. Pharmaxis anticipates approval for the product in Europe by the close of 2010, with promotional activities beginning in 2011.

“Bronchitol is an important advancement in the treatment of cystic fibrosis,” said Gary Phillips, Acting Chief Executive Officer, Pharmaxis. “To get this critical therapy to patients, we need the right partner to ensure our market entry goes smoothly. Europe is a complex area in which to launch a product, and Quintiles’ experience, breadth and expertise in the region made them the ally of choice. They are experts at market access, field sales and product promotion, and understand the nature of the region.”

With 10,000 employees in 30 countries, the Commercial group provides innovative, customized commercial solutions to partners throughout the biopharmaceutical industry by leveraging the full suite of Quintiles’ sales, marketing, clinical, consulting and capital services.

“We are pleased that Pharmaxis – a leading biopharma company – has selected Quintiles to provide a tailored solution to commercialize a much-needed therapy,” said Mark Archer, Vice President of Global Business Development, Quintiles. “As the biopharmaceutical industry moves beyond the traditional commercial sales organization in the New Health, Quintiles is building innovative commercial partnership models that help customers meet the changing demands of prescribers, payers and patients. Quintiles has a broad range of commercial solutions and the agility to help clients accelerate timelines, increase productivity, overcome complexity and demonstrate value.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.